SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Achillion Pharmaceutical, Inc. and Certain Officers --

SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against 
Achillion Pharmaceutical, Inc. and Certain Officers -- ACHN 
NEW YORK, NY -- (Marketwired) -- 11/08/13 --  Pomerantz Grossman
Hufford Dahlstrom & Gross LLP has filed a class action lawsuit
against Achillion Pharmaceuticals, Inc. ("Achillion" or the
"Company") (NASDAQ: ACHN) and certain of its officers. The class
action, filed in United States District Court, District of
Connecticut, and docketed under 13-cv-1479, is on behalf of a class
consisting of all persons or entities who purchased or otherwise
acquired securities of Achillion between April 21, 2012 and September
27, 2013 both dates inclusive (the "Class Period"). This class action
seeks to recover damages against the Company and certain of its
officers and directors as a result of alleged violations of the
federal securities laws pursuant to Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder. 
If you are a shareholder who purchased Achillion securities during
the Class Period, you have until December 7, 2013 to ask the Court to
appoint you as Lead Plaintiff for the class. A copy of the Complaint
can be obtained at www.pomerantzlaw.com. To discuss this action,
contact Robert S. Willoughby at rswilloughby@pomlaw.com or
888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by
e-mail are encouraged to include their mailing address, telephone
number, and number of shares purchased. 
Achillion is a biopharmaceutical company that discovers and develops
solutions for infectious diseases such as HIV, hepatitis, and
resistant bacterial infections. The Company focuses its research and
development on products for the antiviral and antibacterial markets. 
The Complaint alleges that throughout the Class Period, Defendants
made false and/or misleading statements, as well as failed to
disclose material adverse facts about the Company's business,
operations, and prospects, including the safety and suitability of
its premier investigative drug for the treatment of hepatitis,
sovaprevir. Defendants failed to inform investors that sovaprevir in
fact did not interact well with other drugs commonly administered to
treat hepatitis and/or HIV. Specifically, the Company misled
investors to believe that even though patients in the Company's
clinical trials for sovaprevir had elevations in liver enzymes, that
these liver enzymes elevations were transient and returned to
baseline values and were attributable to non-drug-related factors. As
a result of the foregoing, the Company's statements were materially
false and misleading at all relevant times. 
On July 1, 2013, the Company disclosed that the FDA instituted a
clinical hold on "sovaprevir after elevations in liver enzymes
associated with significantly higher than anticipated exposures to
atazanavir and sovaprevir were noted in a Phase I healthy subject
drug-drug interaction study evaluating the effects of concomitant
administration of sovaprevir with ritonavir-boosted atazanavir." As a
result of this disclosure, Achillion shares declined $2.10 per share
or over 25%, to close at $6.26 per share on July 2, 2013. 
On September 27, 2013, after the market closed, the Company disclosed
that the FDA had continued its clinical hold on sovaprevir, after,
"the FDA concluded that the removal of the clinical hold is not
warranted." As a result of this disclosure, Achillion shares declined
$4.22 per share or over 58%, to close at $3.02 per share on September
30, 2013. 
The Pomerantz Firm, with offices in New York, Chicago, Florida, and
San Diego, is acknowledged as one of the premier firms in the areas
of corporate, securities, and antitrust class litigation. Founded by
the late Abraham L. Pomerantz, known as the dean of the class action
bar, the Pomerantz Firm pioneered the field of securities class
actions. Today, more than 70 years later, the Pomerantz Firm
continues in the tradition he established, fighting for the rights of
the victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com. 
CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
rswilloughby@pomlaw.com 
 
 
Press spacebar to pause and continue. Press esc to stop.